The firm also said this week that it plans to submit data to the FDA from an adjuvant trial of giredestrant in ER-positive, HER2-negative breast cancer.
The firms submitted data from the Phase III DESTINY-Breast05 trial comparing Enhertu to Roche's antibody-drug conjugate Kadcyla.
The House of Lords science and technology committee seeks answers to questions regarding the implementation of treatments like CAR T-cell and gene therapies.
The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.
After a data monitoring committee saw increased risk of secondary blood cancers in the SYPHONY-1 trial, the firm will stop selling the drug for follicular lymphoma and sarcoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results